Last Posted: Nov 14, 2019
- Incidence of germline BRCA1/2 mutations in women with tubo-ovarian high-grade serous carcinomas with and without serous tubal intra-epithelial carcinomas.
Dowson Cassandra B et al. International journal of gynecological cancer : official journal of the International Gynecological Cancer Society 2019 Nov - Contralateral prophylactic mastectomy rate and predictive factors among patients with breast cancer who underwent multigene panel testing for hereditary cancer.
Elsayegh Nisreen et al. Cancer medicine 2018 7(6) 2718-2726 - Parent of origin differences in psychosocial burden and approach to BRCA risk management.
Hesse-Biber Sharlene et al. The breast journal 2019 Oct - Position Statement on Direct to Consumer Genetic Testing
Royal College of General Practitioners, November 2019 - Year in Review: Ovarian Cancer: PARP inhibitors, genetic testing, and novel combinations
I Ingram, Medpage Today, November 1, 2019 - The BRCA gene is about so much more than breast cancer risk
A Goldman, Well and Good, October 27, 2019 - Prevalence of BRCA1 and BRCA2 Mutations Among High-Risk Saudi Patients With Breast Cancer.
Abulkhair Omalkhair et al. Journal of global oncology 2018 41-9 - The clinical features associated with mutated BRCA1 and 2 genes in ovarian cancer patients.
Kubelac Paul et al. Journal of B.U.ON. : official journal of the Balkan Union of Oncology 24(4) 1538-1543 - Does preventive oophorectomy increase the risk of depression in BRCA mutation carriers?
Kotsopoulos Joanne et al. Menopause (New York, N.Y.) 2019 Oct - PARP Inhibitors Show Promise as Initial Treatment for Ovarian Cancer
NCI, October 29, 2019
.png)
No hay comentarios:
Publicar un comentario